AU2001280699A1 - Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder - Google Patents

Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder

Info

Publication number
AU2001280699A1
AU2001280699A1 AU2001280699A AU8069901A AU2001280699A1 AU 2001280699 A1 AU2001280699 A1 AU 2001280699A1 AU 2001280699 A AU2001280699 A AU 2001280699A AU 8069901 A AU8069901 A AU 8069901A AU 2001280699 A1 AU2001280699 A1 AU 2001280699A1
Authority
AU
Australia
Prior art keywords
group
derivative
alkyl group
mania
bipolar disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280699A
Other languages
English (en)
Inventor
Meir Bialer
Mitchell Shirvan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2001280699A1 publication Critical patent/AU2001280699A1/en
Assigned to YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM reassignment YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM Request for Assignment Assignors: TEVA PHARMACEUTICAL INDUSTRIES, LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001280699A 2000-07-21 2001-07-20 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder Abandoned AU2001280699A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22010200P 2000-07-21 2000-07-21
US60220102 2000-07-21
PCT/US2001/023116 WO2002007677A2 (en) 2000-07-21 2001-07-20 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder

Publications (1)

Publication Number Publication Date
AU2001280699A1 true AU2001280699A1 (en) 2002-02-05

Family

ID=22822065

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280699A Abandoned AU2001280699A1 (en) 2000-07-21 2001-07-20 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder

Country Status (16)

Country Link
US (2) US6555585B2 (zh)
EP (1) EP1303289A4 (zh)
JP (1) JP2004520263A (zh)
KR (1) KR100843703B1 (zh)
CN (1) CN1251758C (zh)
AU (1) AU2001280699A1 (zh)
CA (1) CA2416821A1 (zh)
CZ (1) CZ2004266A3 (zh)
HU (1) HUP0600526A2 (zh)
IL (1) IL153942A0 (zh)
MX (1) MXPA03000547A (zh)
NO (1) NO20030295L (zh)
NZ (1) NZ523917A (zh)
PL (1) PL365588A1 (zh)
WO (1) WO2002007677A2 (zh)
ZA (1) ZA200300641B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100843703B1 (ko) * 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도
AU2003289782A1 (en) * 2002-12-16 2004-07-09 The University Of British Columbia Valproic acid analogues and pharmaceutical compositions thereof
US20040176463A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Immediate release formulation of n-(2-propylpentanoyl)glycinamide
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
IL156203A0 (en) * 2003-05-29 2003-12-23 Yissum Res Dev Co Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
US20060004098A1 (en) 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2006012603A2 (en) * 2004-07-22 2006-02-02 Nps Pharmaceuticals, Inc. Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
WO2007028030A2 (en) * 2005-09-02 2007-03-08 Picobella, Llc Oncogenic regulatory rnas for diagnostics and therapeutics
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
CA2936158C (en) 2014-02-05 2023-06-13 Yeda Research And Development Co. Ltd. Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease
KR102635938B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU988188A3 (ru) 1973-12-14 1983-01-07 Эсакмадьяросаги Ведьимювек (Инопредприятие) Способ получени N,N-дизамещенных амидов карбоновых кислот
DE3050800C2 (zh) 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be
US4301176A (en) * 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
FR2489319A1 (fr) 1980-08-27 1982-03-05 Clin Midy Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant
BE885303A (fr) 1980-09-19 1981-03-19 Continental Pharma Glycinamides
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
DK373383A (da) 1982-08-20 1984-02-21 Midit Fremgangsmaade til fremstilling af omega-aminosyrederivater
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3785667T2 (de) 1986-09-17 1994-07-21 Clintec Nutrition Co Zusatznahrung bzw. therapie für personen mit risiko oder in behandlung für arteriosklerotische vaskuläre, kardiovaskuläre und/oder thrombotische erkrankungen.
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
CN1494907A (zh) 1996-03-25 2004-05-12 治疗疼痛的药物组合物
IL121268A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
KR20010071572A (ko) 1998-06-22 2001-07-28 아메리칸 바이오지네틱 사이언스, 인코포레이티스 발프로산 유사체를 편두통 및 기분 장애의 치료 및 예방에사용하는 용도
KR100843703B1 (ko) * 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도

Also Published As

Publication number Publication date
NO20030295D0 (no) 2003-01-20
NO20030295L (no) 2003-01-20
WO2002007677A2 (en) 2002-01-31
MXPA03000547A (es) 2004-04-05
WO2002007677A3 (en) 2002-05-30
KR100843703B1 (ko) 2008-07-04
EP1303289A4 (en) 2009-08-05
ZA200300641B (en) 2004-01-26
US20030212142A1 (en) 2003-11-13
CA2416821A1 (en) 2002-01-31
US20020103237A1 (en) 2002-08-01
NZ523917A (en) 2004-11-26
IL153942A0 (en) 2003-07-31
JP2004520263A (ja) 2004-07-08
CN1446097A (zh) 2003-10-01
KR20030036610A (ko) 2003-05-09
CN1251758C (zh) 2006-04-19
HUP0600526A2 (en) 2006-11-28
CZ2004266A3 (cs) 2005-02-16
US6555585B2 (en) 2003-04-29
EP1303289A2 (en) 2003-04-23
PL365588A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
US6555585B2 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
JP4154237B2 (ja) 異痛症および他の種々のタイプの慢性疼痛または幻肢痛を治療するための化合物のペプチドクラスの新規使用
KR101517133B1 (ko) 상승적 항경련 효과를 갖는 약제학적 조성물
KR101518427B1 (ko) 상승적 항경련 효과를 갖는 약제학적 조성물
DE60127459T2 (de) Verwendung von aminosäurehaltigen Antikonvulsiva zur Behandlung von Schmerz
JPH04210915A (ja) 神経変性疾患用治療剤
KR20100014392A (ko) 섬유근통 치료용 드록시도파 및 약학 조성물
NZ524687A (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
JP2006298929A (ja) 炎症性疾患の処置用医薬の製造におけるガバ類縁体、たとえばガバペンチンの使用
KR20010071572A (ko) 발프로산 유사체를 편두통 및 기분 장애의 치료 및 예방에사용하는 용도
AU2007200901B2 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
Thompson et al. Dextromethorphan and its combination with phenytoin facilitate kindling
JP2021512065A (ja) 三叉神経疼痛の予防及び治療のためのｎｅｐ及びａｐｎ阻害薬の形態である、ジスルファニル基を含んだアミノ酸誘導体
JP4362457B2 (ja) 神経因性疼痛治療剤
Velíšek et al. Hippocampal afterdischarges in rats. I. Effects of antiepileptics
AU2001288308B2 (en) Valproic acid derivatives for the treatment of pain
EP1896031B1 (en) Thiazolopyrimidines for use in therapy
AU2001288308A1 (en) Valproic acid derivatives for the treatment of pain

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW

Free format text: FORMER APPLICANT(S): YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM; TEVA PHARMACEUTICAL INDUSTRIES, LTD.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted